baber/WOPTO huggingface dataset:
Patent NZ-553160-A (NZ)
Title: Anilino-substituted triazolophthalazine derivatives having PDE2 inhibitory activity
Inventor: SCHMIDT BEATE
IPC: A61K31/5025
Filed: 2005-08-31
Abstract: Disclosed are anilino-substituted triazolophthalazine derivatives of formula (I), wherein the variables are as defined in the specification. Pharmaceutical composition comprising these triazolophthalazine derivatives are therapeutically effective for antagonizing the effects of the cyclic nucleotide phosphodiesterase of type 2 (PDE2), ameliorating the symptoms of an PDE2-mediated disorder, and are useful for preventing or treating PDE2-mediated disorders particularly for treating (1) conditions associated with pathologically enhanced neoangiogenesis such as all kinds of tumors (benign or malignant) or (2) all kinds of inflammatory diseases associated with neoangiogenesis such as disorders of the arthritis type.
Patent NZ-553461-A (NZ)
Title: Flexible hydraulic compositions
Inventor: DUBEY ASHISH
IPC: C08K3/00
Filed: 2005-09-16
Abstract: Disclosed is a composition for the manufacture of articles comprising: a hydraulic component comprising at least 55% Class C fly ash; about 10% to about 25% of a water-soluble, film-forming polymer on a dry, weight basis; and water.
Patent NZ-554773-A (NZ)
Title: Ocean-Going Vessels
Inventor: CONTI UGO
IPC: B63B7/08
Filed: 2005-11-09
Abstract: A method of adding a flexible fuel tank (54) within an inflatable hull (60) comprising : gluing an open frame to the inflatable hull; cutting away the portion of the inflatable hull circumscribed by the open frame; passing a flexible fuel tank having a hose assembly (62) coupled between the flexible tank and a mounting plate through the opening in the open frame into the inflatable hull; passing the hose assembly an mounting plate through the open frame into the inflatable hull; and, reorienting the mounting plate relative to the open frame and connecting the mounting plate and the open frame.
Patent NZ-556156-A (NZ)
Title: Process for producing acetate salts of polypeptides using hydrogenolysis
Inventor: DOLITZKY BEN-ZION
IPC: A61K31/74
Filed: 2006-01-20
Abstract: Disclosed is a process for making a mixture of acetate salts of polypeptides using hydrogenolysis. Each salt has a desired peak molecular weight and consists of glutamic acid, alanine, tyrosine and lysine.
Patent NZ-563656-A (NZ)
Title: Method for producing a thermoplastic plastic film, film and use thereof
Inventor: GUENATEN CLAUDE
IPC: B29C48/08
Filed: 2005-11-24
Abstract: A thermoplastic foil which is between 10 to 150 mm with a birefringence (Birefringence or double refraction is the decomposition of a ray of light into two rays - the ordinary ray and the extraordinary ray) which will cause a maximum displacement of 25 nm to the optical path of a perpendicular beam of light passing through the thermoplastic foil. A further characteristic of the thermoplastic foil is that there will be no region within any 12 cm diameter circle on the surface of the thermoplastic foil that will deflect a perpendicular beam of light by more than 0.8 angular minutes. The maximum vertical birefringence of the thermoplastic foil is 0.0004.
Patent NZ-567257-A (NZ)
Title: Method of cracking a crude product to produce additional crude products
Inventor: MO WEIJIAN
IPC: C10G1/00
Filed: 2006-10-20
Abstract: Disclosed is a method for producing a crude product, comprising: producing formation fluid from a subsurface in situ pyrolysis heat treatment process; separating the formation fluid to produce a liquid stream and a first gas stream, wherein the first gas stream comprises olefins; fractionating the liquid stream to produce one or more crude products, wherein at least one of the crude products has a boiling range distribution from 38 degrees Celsius and 343 degrees Celsius as determined by ASTM Method D5307; and catalytically cracking the crude product having the boiling range distribution from 38 degrees Celsius and 343 degrees Celsius by a fluidizable cracking catalyst comprising a molecular sieve having cracking activity dispersed in a porous, inorganic refractory oxide matrix or binder to produce one or more additional crude products comprising gasoline hydrocarbons having an octane number of at least 70, wherein at least one of the additional crude products is a second gas stream, and the second gas stream has a boiling point of at most 38 degrees Celsius at 0.101 Mpa and comprises hydrocarbons having a carbon number of at least 3. Also disclosed the product obtained by said method.
Patent NZ-576694-A (NZ)
Title: Device and process for assays using binding members
Inventor: STEINMETZER KATRIN
IPC: B01J19/00
Filed: 2007-11-06
Abstract: A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network.
Patent NZ-584372-A (NZ)
Title: Method of producing nucleosides
Inventor: JUNGMANN OLIVER
IPC: C07H19/06
Filed: 2008-10-10
Abstract: Disclosed is a method of producing a free nucleoside compound, with the proviso that the compound 2'-deoxy-5-azacytidine (Decitabine) is excluded, by reacting a glycoside donor with a protected nucleoside base, in a suitable anhydrous solvent and in the presence of a catalyst, whereby a blocked nucleoside compound is obtained, and removing the protecting groups from said blocked nucleoside compound in order to obtain the free nucleoside compound, wherein said catalyst is selected from the group comprising salts of an aliphatic sulphonic acid and/or salts of a strong inorganic acid containing a non-nucleophilic anion.
Patent NZ-585269-A (NZ)
Title: Betz limit overcoming wind turbine with inflow mixers and injectors
Inventor: PRESZ WALTER M
IPC: F03D1/04
Filed: 2008-09-23
Abstract: 585269 Disclosed is a method for extracting energy over the Betz limit for an axial flow wind turbine. The axial flow fluid turbine has an impeller encircled by a turbine shroud with a flared inlet and a terminus end, the impeller being downstream of the flared inlet. A primary fluid stream of ambient fluid is received and directed into the flared inlet and through the turbine shroud of the axial flow turbine, the turbine shroud having a length less than a maximum outer diameter of the turbine shroud. Energy is extracted from the primary fluid stream with the impeller that is encircled by the turbine shroud, resulting in a lower energy primary fluid stream. A secondary fluid stream of ambient fluid that bypassed the turbine shroud is entrained and mixed with the lower energy primary fluid stream via a mixer at the terminus end of the turbine shroud and an ejector. The secondary bypass fluid stream is a higher energy fluid stream than the lower energy primary fluid stream, the mixer guiding at least a portion of the secondary bypass fluid stream inward towards a centre axis of the turbine shroud along an outer surface of the turbine shroud to mix the higher energy secondary bypass fluid stream with the lower energy primary fluid stream downstream of the terminus end of the turbine shroud.
Patent NZ-590327-A (NZ)
Title: Methods for dosing an activin-actriia antagonist and monitoring of treated patients
Inventor: SHERMAN MATTHEW L
IPC: C07K14/00
Filed: 2009-06-26
Abstract: NZ 590327 Disclosed is a method of making a diagnosis in a patient that has been treated with, or is a candidate to be treated with, an Activin Receptor Type IIa (ActRIIa) polypeptide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 3 as defined in the complete specification. The disclosed method comprises: monitoring in a sample obtained from the patient one or more hematologic parameters selected from red blood cell levels, haemoglobin levels, iron stores, transferrin saturation, ferritin levels, and haematocrit levels; determining whether the sample indicates that the patient has one or more hematological parameters selected from: a red blood cell level greater than the normal range for patients of similar age and sex; a hemoglobin level of greater than the normal range for patients of similar age and sex; iron stores that are lower than the normal range for patients of similar age and sex; a transferrin saturation of less than 20%; a ferritin level of less than 100 ng/ml; and a hematocrit level greater than the normal range for patients of similar age and sex; and making a diagnosis that dosing with the ActRIIa polypeptide be reduced, delayed, or terminated in the patient for whom a determination in step (ii) is affirmative.
Patent NZ-591130-A (NZ)
Title: Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
Inventor: LANGERMAN SOLOMON
IPC: C07K14/00
Filed: 2009-08-25
Abstract: Disclosed is a therapeutic composition, comprising (a) a compound that binds to PD-1 and (b) cyclophosphamide or an analogue of cyclophosphamide in a pharmaceutically acceptable carrier, wherein said compound is a fusion protein comprising first and second peptide portions, wherein said first peptide portion comprises an amino acid sequence selected from: wild type B7-DC, an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1 and which competes in vitro with wild-type B7-DC for binding to PD-1, a fragment of B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1, and an extracellular domain of B7-DC and said second peptide portion comprises a portion of an immunoglobulin. Further disclosed is the use of the therapeutic composition in the manufacture of a medicament for the treatment of cancer or infectious disease.
Patent NZ-596739-A (NZ)
Title: Methods of treating proliferative diseases
Inventor: JAMES JOYCE K
IPC: A61K31/429
Filed: 2010-05-14
Abstract: 596739 Disclosed herein is the use of N-(5-tert-butyl-isoxazol-3-yl)-N’-{ 4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl} urea (I), or a pharmaceutically acceptable salt or solvate thereof, in the treatment of a proliferative disease. Specifically disclosed are dosing, dosing schedules or dosing regimens such as administration of the compound on an empty stomach in a dosage of 12 mg to 200 mg of the compound per day. The proliferative disease may be a cancer, such as leukaemia. Additionally disclosed are specific patient groups, such as wherein the patient is relapsed or refractory.
Patent NZ-597518-A (NZ)
Title: Self righting crane hooks
Inventor: EASTALL JONATHAN F
IPC: B66C1/24
Filed: 2012-01-10
Abstract: 597518 A lifting hook 2 for lifting a coil including a lifting frame 4 having a lifting point 4, an elongate coil support member 20 supported by the frame 4 and extendible and retractable relative thereto, an extendible and retractable backstop member 16 arranged to present a coil abutment face at a desired position relative to the lifting point 4 for balancing the hook 2 when loaded, and a mechanical linkage connecting the elongate coil support member 20 to the backstop member 16 and arranged to extend the backstop member 16 upon retraction of the elongate coil support member 20 and to retract the backstop member 16 upon extension of the elongate coil support member 20.
Patent NZ-597930-A (NZ)
Title: Chromone derivatives, a process for their preparation and their therapeutic applications
Inventor: RIEU JEAN-PIERRE
IPC: A61K31/496
Filed: 2010-08-31
Abstract: Abstract 597930 The present disclosure relates to chromone derivatives, their preparation, their pharmaceutical compositions and their application as D3 dopaminergic ligands as a medicament for disorders of the central nervous system. Conditions that may be treated using the disclosed compounds include: Parkinson's disease, psychosis, schizophrenia, dyskinesias associated with Parkinson's disease,cognitive deficiency optionally associated with age or with Alzheimer's disease, mood disorder, essential tremor, anxiety, depression, bipolar disorder, sexual impotence, premature ejaculation, alcoholism and nicotine addiction. Specifically disclosed compounds include but are not limited to: 6,7-dimethoxy-3-{ 4-[4-(2-methoxyphenyl)-piperazin-1-yl]-butyl} -chromen-4-one 5-{ 4-[4-(6,7-dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]-piperazin-1-yl} -1H-quinolin-2-one N-(3-{ 4-[4-(6,7-dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]-piperazin-1-yl} -phenyl)-acetamide 2-methoxyethanesulfonic acid (3-{ 4-[4-(8-oxo-8H-[1,3]dioxolo[4,5-g]chromen-7-yl)-butyl]-piperazin-1-yl} -phenyl)-amide And 4-{ 4-[4-(6,7-dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]-piperazin-1-yl} -1,3-dihydrobenzimidazol-2-one.
Patent NZ-600229-A (NZ)
Title: Triazolopyridines
Inventor: SCHULZE VOLKER
IPC: A61K31/4196
Filed: 2010-11-17
Abstract: Disclosed herein are triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1, also known as Tyrosine Threonine Kinase, TTK) inhibitors, in which R1, R2, R3, R4, and R5 are defined in the specification, to methods of preparing the compounds, to pharmaceutical compositions and combinations comprising the compounds, to the use of the compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases such as uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, as well as to intermediate compounds useful in the preparation of the compounds. In one embodiment the compound is 2-(4-methylpiperazin-1-yl)-N-[4-(2-{ [2-(trifluoromethyl)phenyl]amino} [1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide.
Patent NZ-600800-A (NZ)
Title: Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
Inventor: LEE CHRISTOPHER A
IPC: A61P35/00
Filed: 2010-12-21
Abstract: The disclosure relates to a form 1 and form 2 polymorph of (-)-trans -3 -(5,6- dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione. The present disclosure also relates to (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4- (1H-indol-3-yl) pyrrolidine-2, 5-dione compounds having a chiral purity greater than 99%, and methods of preparation of these compounds. Also disclosed are pharmaceutical compositions comprising these (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione compounds, which are suitable for treating a cell proliferative disorder, such as a cancer.
Patent NZ-605708-A (NZ)
Title: A trap
Inventor: BOND CRAIG RICHARD
IPC: A01M27/00
Filed: 2010-03-03
Abstract: A trap includes a source of compressed gas 2, a trigger mechanism configured to be actuated by an animal, and a kill mechanism 3 including a piston 22 powered by compressed gas and a hammer 23 or striking element formed integrally with the piston or carried on an end of the piston 22.When the trigger mechanism is actuated by an animal, gas flows to actuate the piston 22 of the kill mechanism, which is arranged to move the hammer 23 or striking element to strike or cut the animal, thereby killing the animal.
Patent NZ-612592-A (NZ)
Title: Process for the enzymatic synthesis of (7s)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) n-methyl methanamine, and application in the synthesis of ivabradine and salts thereof
Inventor: FRANCOIS LEFOULON
IPC: C07D223/16
Filed: 2013-06-27
Abstract: The disclosure relates to a process for the enzymatic synthesis of the compound of formula (I), (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-y1) N-methyl methanamine by enzymatic acylation of the racemic amine of formula (IV) to yield the carbamate of formula (IX), which is then reduced using a reducing agent selected from LiAlH4 and Red-Al to yield the compound of formula (I); the compound of formula (I) subsequently is either coupled with a compound of formula (X) or, in the presence of a reducing agent, subjected to a reductive amination reaction with a compound of formula (XI) to yield 3-{ 34 { [(7S)-3,4-dimethoxybicyclo [4.2.0]octa-1,3,5-trien-7-yl] methyl} (methypamino]-propyl} -7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one (commonly known as ivabradine, which is represented by formula (II)), which is then converted into an addition salt with a pharmaceutically acceptable acid, in anhydrous or hydrate form, wherein the compounds of formulae (IV), (IX), (X) and (XI) are as shown in the specification.
Patent NZ-615109-A (NZ)
Title: Tipping actuator for a conveyor system
Inventor: WHITE SHELDON PHILLIP
IPC: B65G17/16
Filed: 2012-09-06
Abstract: Disclosed are a tipping actuator (10) and a conveyor system. The disclosure notes that conveyors used in grading systems for articles such as fruit include article carriers which discharge the articles. Triggers activated by a solenoid and spring cause the article carrier to tip violently resulting in damaged fruit. The present tipping actuator (10) is shaped to ease contact between the trigger means (13) and the article carriers. The tipping actuator (10) is suitable for use with a conveyor system. The conveyor system comprises a plurality of article carriers moving on an endless conveyor in a conveying direction. Each article carrier has a carrier frame for bearing an article. The carrier frame is pivotally mounted on the article carrier and is operable to tip enabling discharge of the article borne on the carrier frame. The tipping actuator (10) comprises trigger means (13) and trigger actuation means. The trigger means (13) has at least one contact portion (14) for contacting the article carriers. The trigger actuation means is operable to move the trigger means into a contact position in which the contact portion(s) (14) is positioned in the path of the article carriers to make contact therewith effecting tipping thereof. The contact portion(s) (14) comprise at least one contact surface. The contact surface(s) comprises at least three surface sections (101, 102, 103) of different gradients. The relative gradients of the at least three surface sections (101, 102, 103) reduce in steepness in the conveying direction. At least two of the surface sections (101, 102, 103) slope upwards in the conveying direction.
Patent NZ-616399-A (NZ)
Title: Fruity flavored cocoa products and processes for producing such cocoa products
Inventor: ANIJS HARROLD GLENN
IPC: A23L27/29
Filed: 2012-04-09
Abstract: Discloses a cocoa product selected from the group consisting of a cocoa powder, a cocoa liquor, and a cocoa butter, the cocoa product having a fruity flavour comprising: an increased amount of a fruity aroma compounds, wherein the fruity aroma compounds are selected from the group consisting of furaneol, phenylacetaldehyde, ethyl-2-methylpropanoate, ethyl-2-methylbutanoate, ethyl-3-methylbutanoate, and combinations of any thereof; wherein the cocoa product comprises an amount of fruity aroma compounds selected from the group consisting of at least 5 μg/kg of ethyl-2-methylpropanoate, at least 15 μg/kg of ethyl-2-methylbutanoate, at least 20 μg/kg of ethyl-3-methylbutanoate, at least 50 μg/kg of phenylacetaldehyde, at least 100 μg/kg of furaneol, and combinations of any thereof.
Patent NZ-623622-A (NZ)
Title: Combination therapy for ovarian cancer
Inventor: CHAN EDWARD MICHAEL
IPC: A61P35/00
Filed: 2012-10-31
Abstract: The disclosure relates to the use of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (also called ralimetinib or LY2228820) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of ovarian cancer wherein said medicament is to be administered in combination with gemcitabine and a platinum agent selected from cisplatin and carboplatin.
Patent NZ-705261-A (NZ)
Title: Cooling circuit, dry cooling installation and method for controlling the cooling circuit
Inventor: BALTUS FRITS CORNELIS A
IPC: G05D23/19
Filed: 2013-07-22
Abstract: Problems exist with some heat exchangers of previously proposed drying systems, including unstable control, fluctuating levels of superheating and fluctuating temperatures at the outlet of the heat exchangers. The present disclosure relates to a cooling circuit (2) capable of controlling expansion valves (7, 7A, 7B) by means of a control unit (18). The control unit (18) is provided with an algorithm for controlling the lowest gas temperatures of separate heat exchangers (11, 11A, 11B) according to the same target value, by separately controlling the respective expansion valves (7, 7A, 7B) of each respective heat exchanger (11, 11A, 11B) on the basis of a difference between a measured lowest gas temperature of the heat exchanger (11, 11A, 11B) belonging to the expansion valve (7, 7A, 7B) and the target value.
Patent NZ-712514-A (NZ)
Title: Wind turbine and wind turbine tower
Inventor: POLLMANN FRANK
IPC: E06B5/11
Filed: 2014-04-10
Abstract: The invention relates to a wind turbine having a tower (102) comprising an access door (300). The access door (300) has a door lock and, on its outside, a deflector plate (310), said plate extending across substantially the full area of the door and having a recessed portion (312). A door knob (307) is provided near the recessed portion (312). An outside of the deflector plate (310) protrudes at least partly beyond the door lock towards the outside.
Patent NZ-716822-A (NZ)
Title: Antiviral compounds
Inventor: BEIGELMAN LEONID
IPC: C07D495/14
Filed: 2014-08-19
Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV). The new antiviral compounds are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, having the structure A–L–Y (I), wherein L is
Patent NZ-724628-A (NZ)
Title: Apparatus for and method of gameplay
Inventor: JORDAN ANTHONY MALCOLM
IPC: A63F9/00
Filed: 2016-09-22
Abstract: The present invention relates to a board game wherein the playing apparatus includes a playing surface, posts for elevating the playing surface, and playing pieces. This board game can encourage team bonding and more social interaction in the growing age of technology. The playing surface is selected from a used or recycled item such as a pizza box or beer carton. Using such items will reduce waste while providing food and beverage companies the option of advertising their product on a board game by reusing existing packaging. The playing surface is generally flat and may be circular or polygonal and also incorporates apertures for posts and/or goals. The playing surface is supported on one or more posts that protrude through the aperture, and have the dual purpose of also providing an obstacle within the game. The playing pieces in the board game generally include discs, counters, bottle tops, coins and/or marbles etc.